Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of long-term debt $4,474,131 $2,651,592 Current portion of capital lease obligation - 41,641 Accounts payable 3,708,060 2,466,052 Accrued expenses 6,060,141 6,182,417 Deferred rent 124,462 124,463 Deferred revenue 1,857,136 1,857,136 --------- --------- Total current liabilities 16,223,930 13,323,301 DEFERRED RENT 48,421 79,793 DEFERRED REVENUE 3,404,674 3,868,965 LONG-TERM DEBT, net 18,053,545 16,522,665 ---------- ---------- Total liabilities 37,730,570 33,794,724 ---------- ---------- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,390,862 and 23,340,498 shares issued and outstanding at December 31, 2008 (unaudited) and September 30, 2008, respectively 23,391 23,340 Warrants to purchase 127,248 and 116,183 shares of common stock for $12.05 per share, as of December 31, 2008, (unaudited) and September 30, 2008, respectively 1,229,767 1,140,114 Additional paid-in capital 147,600,186 145,818,439 Accumulated other comprehensive (loss) income (1,515) (2,604) Accumulated deficit (130,067,341) (111,791,944)
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Kerr Corporation, a ... video and additional how-to information about dual arch impressions on ... with Dual Arch Impressions,” the blog entry serves up a ... and houses a step-by-step demonstration by Dr. David Little as ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... - Sales up 16% - Profit Before R&D up 19% - Net Profit (Group Share) up 12% - ... approved the 2007 consolidated financial statements:, (EUR millions) 2007 ... ... sales % change, Sales ...
... 12 Oncolys BioPharma,Inc. (Tokyo, Japan) and Tacere ... they have entered into a strategic alliance and,license ... interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033,code-named ... the,strategic alliance entered into by Tacere and Oncolys ...
... 12 Mercury Therapeutics,Inc. (MTI), a company that ... announces that it has signed an exclusive license,agreement ... Under this agreement, MTI has licensed to ... AMP-activated protein kinase (AMPK), a well,validated drug target ...
Cached Biology Technology:STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 2STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure 3Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 2Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug 3Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences 2Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences 3
(Date:4/24/2014)... out a welcome mat to bacteria seeking to invade, and ... published this week in the Proceedings of the National ... between microbe and host that researchers can exploit to protect ... plant Arabidopsis puts out a molecular signal that ... hostile army were unknowingly passing by a castle, and the ...
(Date:4/23/2014)... is available in French and German . ... female? In humans and other mammals, the difference between sexes depends ... is present only in males, where the two sexual chromosomes are ... Y is ultimately responsible for all the morphological and physiological differences ... the case. A very long time ago, the X and Y ...
(Date:4/23/2014)... Scarborough research shows that male black widow spiders prefer ... rare example of mate preference by male spiders. ... MacLeod and Maydianne Andrade, a professor in UTSC,s Department ... and the wild that males overwhelmingly chose to mate ... widows can tell whether a potential mate is well-fed ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3Picky male black widow spiders prefer well-fed virgins 2
... marine clouds to cool sea surface temperatures could protect ... Research, published in Atmospheric Science Letters , proposes ... give coral a fifty year ,breathing space, to recover ... last few decades has been caused by rising sea ...
... in the largest continuous salt desert in the world, ... a bacterium that stores large amounts of PHB, a ... food and pharmaceutical industries, for example to produce nanospheres ... polymers to substitute for petroleum-based plastics, scientists have recently ...
... specialized membrane systems, made up of stacked disks linked ... (LMU) in Munich has now identified a protein that ... stack. Scanning electron microscopy (SEM) micrograph of a ... (green) and assimilation starch granules (grey). (Prepared by freeze ...
Cached Biology News:Cloud brightening to cool seas can protect coral reefs 2Bacteria from Salar de Uyuni in Bolivia conceal bioplastic 2Photosynthesis: Membranes in tight corners 2
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Monoclonal antibodies conjugated with rhodamine...
... compact and lightweight, the Moticam 2300 camera ... the eyepiece, eyetube, or trinocular port. Included ... use Plug-and-Play Images 2.0ML software offers quick ... tools to maximize resolution for examination or ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: